<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03609541</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol DG2.0-08.05.2018</org_study_id>
    <nct_id>NCT03609541</nct_id>
  </id_info>
  <brief_title>Evaluation of Biomarkers of COPD Exacerbation</brief_title>
  <official_title>Evaluation of Biomarkers of COPD Exacerbation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Serum amlyoid A (SAA) was shown to act as biomarker for exacerbation of chronic obstructive
      pulmonary disease (AE-COPD). It seems that SAA triggers chronic inflammation by binding to
      ALX/PFR2 receptor. In contrast, lipoxin A4 seems to inhibit the inflammatory processes by
      binding to ALX/PFR2 receptor. A small trial has already demonstrated an imbalance between SAA
      and lipoxin A4 during AE-COPD. This study evaluates SAA level and SAA/lipoxin A4 ratio in
      patients with stable COPD and AE-COPD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient enrolment and data aquisition is to be carried out on a prospective basis. It is
      planned to enrol 40 patients with stable COPD and 40 patients with AE-COPD. All patients will
      undergo blood sampling inlcuding SAA and Lipoxin A4.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">July 2018</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SAA</measure>
    <time_frame>time of exacerbation/hospitalisation, an average of 3 days</time_frame>
    <description>SAA level in stable COPD and COPD exacerbation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SAA/lipoxin A4 ratio</measure>
    <time_frame>time of exacerbation/hospitalisation, an average of 3 days</time_frame>
    <description>SAA/lipoxin A4 ratio in stable COPD and COPD exacerbation</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>SAA Level and SAA/Lipoxin A4 Ratio</condition>
  <arm_group>
    <arm_group_label>Patient with stable COPD</arm_group_label>
    <description>Evaluation of serum amlyoid A, lipoxin A4, CRP and fibrinogen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient with COPD exacerbation</arm_group_label>
    <description>Evaluation of serum amlyoid A, lipoxin A4, CRP and Fibrinogen at beginning and at the end of COPD exacerbation</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sampling
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with COPD GOLD 3-4 confirmed by anamnesis and pulmonary function test (stable COPD
        and COPD exacerbation)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with COPD GOLD 3-4 confirmed by anamnesis and pulmonary function test

          -  Patient has provided written informed consent

        Exclusion Criteria:

          -  other reasons for worsening of symptoms (cough, dyspnea): e.g. pneumothorax,
             pneumonia, pulmonary embolism, myocardial infarction.

          -  malignant disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniela Gompelmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thoraxklinik, University of Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniela Gompelmann, MD</last_name>
    <phone>004962213968087</phone>
    <email>daniela.gompelmann@med.uni-heidelberg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Thoraxklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Gompelmann, MD</last_name>
      <phone>+49(0)62213968087</phone>
      <email>daniela.gompelmann@thoraxklinik-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Daniela Gompelmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 16, 2018</study_first_submitted>
  <study_first_submitted_qc>July 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>July 24, 2018</last_update_submitted>
  <last_update_submitted_qc>July 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Daniela Gompelmann</investigator_full_name>
    <investigator_title>PD Dr. med. Daniela Gompelmann</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

